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Abstract: Levels of reactive -ketoaldehydes derived from arachidonate increase in diseases
associated with inflammation and oxidative injury. To assess the biological importance of
these -ketoaldehydes, we previously identified salicylamine as an effective -ketoaldehyde
scavenger in vitro and in cells. To determine if salicylamine could be administered in vivo,
we developed an LC/MS/MS assay to measure salicylamine in plasma and tissues. In mice,
half-life (t1/2) was 62 minutes. Drinking water supplementation (1-10 g/L) generated tissue
concentrations (10-500 M) within the range previously shown to inhibit -ketoaldehydes in
cells. Therefore, oral administration of salicylamine can be used to assess the contribution
of -ketoaldehydes in animal models of disease.
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1. Introduction
Both inflammation and oxidant stress give rise to bicyclic endoperoxides (prostaglandin H2 and H2isoprostanes, respectively) that non-enzymatically rearrange to form highly reactive -ketoaldehydes
(KA) [1,2]. These KAs, termed levuglandins and isoketals, react extremely rapidly to covalently
modify cellular proteins [2] and phosphatidylethanolamine [3]. Levels of KA protein adducts increase
in a number of conditions associated with inflammation and oxidative stress including Alzheimer’s
Disease [4], atherosclerosis [5], myocardial infarction [6], end stage renal disease [5], sepsis [7], and
hyperoxia [8]. Experiments with exogenously added KAs in cell culture experiments suggest that
formation of KA protein adduct may contribute to disease pathogenesis [6,9-15]. To directly test
whether formation of KA protein adducts contribute to disease processes, development of selective
inhibitors that block endogenous formation of KA protein adducts in vivo is required.
To this end, we recently characterized a class of phenolic amines including pyridoxamine (PM) and
its lipophilic analogs such as salicylamine (SA) that inhibit protein modification by acting as KA
scavengers (Figure 1) and that preferentially react with KAs over other lipid carbonyls produced by
peroxidation such as 4-hydroxynonenal [15,16]. In vitro, the reaction rate of PM and its analogs with
KAs is more than a thousand times faster than the reaction rate of lysyl residues. However, as lipid
peroxidation forms KAs esterified in situ to phospholipids [13], lipophilic analogs are anticipated to
be more efficacious than the highly hydrophilic PM. In keeping with this notion, the lipophilic PM
analog SA was a better significantly better inhibitor of KA protein adducts in cells than PM [15].
Additionally, SA protected HepG2 cells from cytotoxicity induced by hydrogen peroxide, while PM
was ineffective [15]. Similarly, SA was able to protect against KA and oxidant-induced sodium
channel function inhibited by KA or oxidants [17]. The protective effect of SA in cultured cells
suggests that it may be a useful tool to study the biological importance of KAs in vivo and to
determine whether inhibiting KAs is a useful therapeutic strategy for the treatment of disease. To
facilitate in vivo studies, we developed an LC/MS/MS assay to measure SA levels in plasma and tissue
and used this assay to explore the pharmacokinetics and oral bioavailability of SA in mice.
2. Experimental Section
Synthesis of isotope-labeled salicylamine
All chemicals and solvents were purchased from VWR International (West Chester, PA) unless
otherwise noted. [2H6]-Phenol (5 g, 50 mmol; Sigma-Aldrich, St. Louis, MO) and anhydrous MgCl2
(7.5 g), were dissolved in acetonitrile (150 ml), and triethylamine (26 ml) and paraformaldehyde
(10.5 g) added. The suspension was refluxed for 1.5 h, cooled, and mixed with 4 M HCl (55 ml) on
ice. It was extracted with ethyl acetate (4  25 ml) and the combined extracts were dried and
evaporated. The crude product was purified by chromatography (silica gel, Fisher Scientific,

Pharmaceutics 2010, 2

20

Pittsburgh, PA; 3:1 hexane-ethyl acetate) and treated with hydroxylamine HCl (3.6 g) and sodium
acetate (4.2 g). The resulting oxime was reduced in two batches (3.7 g) with zinc (6.5 g) and acetic
acid (40 mL) at 10-25 °C for 3 h. The reaction mixtures were combined and filtered through a bed of
Celite (Fisher). The filtrate was evaporated, then co-evaporated with toluene (20 ml) and ethanol
(20 ml). [2H4]SA as acetic acid salt was crystallized from hot ethanol; yield 6.3 g (65%). [14C]phenol
(250 Ci in 5 mmol; ViTrax Radiochemicals, Placentia, CA) was converted to [14C]SA in a similar
manner. Formation of the expected product was confirmed by melting point analysis (186-187 oC) and
UV absorbance spectrum in comparison to previously reported values for salicylamine [18], as well as
by mass spectrometry ([M+H]+ ion m/z 128) for [2H4]SA. Final purity was 98%. Unlabeled SA was
prepared by reduction of salicylaldoxime (Fisher) with zinc and acetic acid.
Figure 1. Arachidonate oxidation generates -ketoaldehydes that rapidly react with cellular
proteins and can cause cell dysfunction and death. Scavengers such as salicylamine and
pyridoxamine selectively react with -ketoaldehydes and thereby inhibit formation of
-ketoaldehyde protein adducts, protecting against -ketoaldehyde induced cell dysfunction
and cell death.
O
PROTEIN
COOH

NH2
PROTEIN

O

OH
ketoaldehyde

COOH

N
OH

NH2
OH
salicylamine

HO

NH2
OH

ketoaldehyde
protein adduct

N+
H
pyridoxamine

-ketoaldehyde scavengers
cell dysfunction/death
COOH

N
OH
inactivated

OH
ketoaldehyde

Measurement of salicylamine lipophilicity
To measure the efficiency of extraction of SA by ethyl acetate, 5,000 dpm [14C]SA was added to
1 ml solutions at pH 5, 7, 7.4, 8, 8.5, 9, and 10. Ethyl acetate (4 ml) was then added, the two phases
separated, and the amount of radiolabel in each determined by liquid scintillation counting. For
measurement of PM extraction efficiency, 1 mM PM solution was prepared in PBS and absorbance
measured at 325 nm. One ml aliquots of these solutions were then brought to pH 5, 7.4, and 9, and
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ethyl acetate (4 ml) added. The two phases were extracted, the ethyl acetate layer dried, resuspended in
1 ml PBS, and the absorbance of the aqueous layer and the ethyl acetate layer determined.
Animals
Twenty five C57BL6 male mice purchased from Jackson Labs (Bar Harbor, ME) and weighing
23-25 g were used for experiments. C57BL6 mice were chosen for these studies because they are the
background strain for many transgenic mouse models of disease related to oxidative stress and
inflammation. For pharmacokinetics studies, SA was dissolved in PBS at 36.8 g/L (200 mM) and
200 mg/kg injected intraperitoneally into ten C57BL6 mice. Two mice each were euthanized at 15, 30,
60, 120, and 240 minutes. Blood was collected, centrifuged, and the plasma layer removed and stored
at -80 oC until analysis. Liver, brain, kidney, heart were also collected and flash frozen in liquid
nitrogen and then stored at -80 oC until analysis. For oral bioavailability studies, solutions of SA were
prepared from SA acetate salt at 1 g/L, 3 g/L, and 10 g/L in water. Solutions were transferred to red
colored watering bottles to protect SA from photooxidation. Each of the C57BL6 mice were caged
individually and given food and medicated water ad libitum. At the end of the feeding period, animals
were euthanized in the morning and tissue and plasma collected. All procedures involved in the study
were approved by the Vanderbilt’s Institutional Animal Care and Use Committee.
Salicylamine assay
For plasma samples, 50 l of the sample were added to 450 l PBS containing 65 pmol of [2H4]SA.
For tissue, the flash frozen organ was weighed, placed in 5 ml PBS, homogenized, and 65 pmoles of
[2H4]SA was added to 500 l of the homogenate for analysis. Phenyl isothiocyanate (PITC) working
solution (2:2:6 PITC/triethylamine/acetonitrile v/v/v) was prepared fresh each day, and 30 l of this
solution, along with 500 l acetonitrile, added to the sample to form SA-PITC (Figure 2). Samples
were incubated at 60 oC for 40 minutes in darkness.
The derivatized samples were then extracted twice with 500 l ethyl acetate, samples dried under
nitrogen, and dissolved in 50 l 20% methanol. Samples were analyzed by HPLC (ThermoFinnigan
Surveyor MS pump; San Jose, CA) coupled to a triple quad mass spectrometer (ThermoFinnigan TSQ
Quantum) using reversed phase chromatography (Magic Bullet C18 column 3A, Michrom
BioResources, Auburn, CA) with the gradient programmed from 90% solvent A (water with 0.1%
acetic acid) to 100% Solvent B (methanol with 0.1% acetic acid) over 4.0 minutes and then continuing
at 100% B for an additional 1.0 minutes. Flow rate was 200 l/min. Eluant was coupled directly to the
mass spectrometer operated in multiple reaction monitoring (MRM) positive ion mode. Nitrogen was
used for both the sheath and the auxiliary gases. The sheath and auxiliary gases were set to 49 and 15
(arbitrary units), respectively. The electrospray needle was maintained at 4000 V. The ion-transfer
tube was operated at 35V and 250 °C. The tube lens voltage was set to 96 V. For analysis of
underivatized SA and [2H4]SA, MRM was performed at m/z 124.1 107.0 @-25 eV and m/z 128
111.0 @-25 eV, respectively. These transitions result from loss of the amine from the parent
compound. For SA-PITC and [2H4]SA-PITC, MRM were performed at m/z 259.1 153.0 @-15 eV
and m/z 263.1153.0 @-15 eV. These transitions result from fragmentation of the thioamide bond
and the product ion represents the fragment derived from the PITC moiety. Additional MRM at
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m/z 259.1 107.0 @-25 eV and m/z 263.1111.1@-25 eV for SA-PITC and [2H4]SA-PITC,
respectively, for each product were also monitored for verification. These transitions result from
fragmentation at the same thioamide bond as above, but the product ion represents the fragment
derived from the SA moiety. The scan width for product ions was 0.5 m and the cycle time for each
ion was 0.05 s. The electron multiplier gain was set to 2 x 106. The concentration of SA in plasma and
tissue were calculated from the ratio of SA-PITC and [2H4]SA-PITC peak height.
Figure 2. Reaction of PITC with salicylamine to form SA-PITC.
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Pharmacokinetic Analysis
For data obtained from intraperitoneal SA administration, half-life (t1/2) was estimated by linear
regression of the log-concentration vs. time profile of mean plasma levels between 30 and 240 min.
The resulting slope furnished the elimination rate constant (ke) and t1/2 was calculated by:

t1 
2

Ln 2
ke

(1)

Apparent clearance (CL/Fapp) was calculated by obtaining the area under the SA plasma
concentration – time curve (AUC) using the assumption that SA injected i.p. was fully bioavailable,
(i.e., that the apparent fraction of absorbance (Fapp ) was 1), with the following relationship:

CL Dose

Fapp AUC

(2)

Apparent volume of distribution (V/Fapp), again assuming Fapp was 1, was calculated by modelindependent methods using the relationship:

V
Dose  AUMC

Fapp
AUC 2

(3)

where AUMC is the area under the first moment (concentration × time) vs. time curve.
Calculations were performed in Microsoft Excel. All graphs were generated in GraphPad Prism
version 4.03 software (La Jolla, CA).
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3. Results and Discussion

Development of method to assay SA in biological tissue
The greater bioactivity of SA compared to PM as a KA scavenger has been ascribed to its
potentially greater lipophilicity. The methyl amine moieties of both SA and PM have a pKa of 7.9, so
that a portion of the methyl amine is uncharged (deprotonated) for both molecules at physiological pH.
However, for pyridoxamine, the pyridine nitrogen remains positively charged (protonated) at
physiological pH, so that its partitioning into lipid bilayers would be disfavored. To determine optimal
extraction conditions for measurement of SA and to also directly compare lipophilicity of SA and PM,
we measured the amount of SA and PM extracted into ethyl acetate at various pH. [14C]SA was spiked
into solutions buffered at a range of pH, extracted with ethyl acetate, and percentage of [14C]SA in the
two phases determined. At physiologically relevant pH 7.4, 15% of the SA partitioned into ethyl
acetate, while less than 1% PM did so (Figure 3). Even at pH 9, less than 1% PM partitioned into ethyl
acetate, while 69% of SA was found in the ethyl acetate layer. These results confirm the greater
lipophilicity of SA compared to PM.
Figure 3. Salicylamine (SA) is more lipophilic than pyridoxamine (PM) and readily
extracts into ethylacetate. [14C]SA was added to solution buffered from pH 5 to 10, four
volumes of ethyl acetate added, and the amount of radiolabeled recovered in the aqueous
and ethyl acetate layer determined by liquid scintillation counting. Similar experiments
were carried out with unlabeled PM, using UV absorbance to detect PM levels.
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LC/MS/MS measurement of SA in plasma and tissue.
We have previously quantified SA during in vitro reactions by LC/MS/MS without any purification
or derivatization [15]. We therefore determined if we could use this same LC/MS/MS method to
measure SA in plasma using only ethyl acetate extraction at pH 9 for purification. Extraction was
performed on 50 l aliquots of plasma spiked with 0 or 10 M SA (final concentration), along with
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65 pmol [2H4]SA internal standard. The resulting chromatograms demonstrated that SA could be
measured by this method, although the sensitivity was low (Figure 4A) (S/N = 9; peak height 1.6E6).
We then assessed the effect of derivatization of SA with phenyl isothiocynanate (PITC) on sensitivity
and chromatography. We found that overall sensitivity for PITC derivatized SA was greater
(S/N = 498, peak height 2.9E7) compared to non-derivatized sample and the derivatized compound
showed greater retention on the C18 column under our gradient conditions (Figure 4B). We therefore
used PITC derivatization for all subsequent analysis.
Figure 4. Analysis of underivatized SA or PITC derivatized SA by LC/MS/MS. A) 0 or
10 uM SA was spiked into 50 l plasma, along with 65 pmol [2H4]SA, and then analyzed
without derivatization by LC/MS/MS as described in the Experimental section. B) 0 or
10 uM SA was spiked into 50 l plasma, along with 65 pmol [2H4]SA, and then subjected
to PITC derivatization prior to analysis by LC/MS/MS as described in the Experimental
section.

Validation of LC/MS/MS method to measure SA
To determine the linearity of the assay, we prepared 10 nM to 1 mM solutions of SA in PBS and
also in plasma. 50 ul aliquot of each sample were added to 65 pmoles [2H4]SA and the samples
analyzed after PITC derivatization and extraction. Increasing concentrations of SA gave a linear
response over all concentrations in PBS (y = 0.995 +0.008 R2 = 0.995). For plasma, the lower limit of

Pharmaceutics 2010, 2

25

detection (S/N > 3) was approximately 100 nM when using 50 l plasma. The accuracy of the assay
from plasma samples spiked with 1M SA was 91% and with 10 M SA was 84%. Precision was
measured in five replicate samples of plasma and livers from animals administered SA. For plasma, the
coefficient of variation was 6%. We also performed precision measurements in homogenized liver
samples. Liver was chosen as a representative tissue for validation of tissue measurements, because in
our previous experience with quantitation other small molecules, this tissue matrix tends to have the
most interfering compounds that hamper sensitivity and reproducibility. When we performed the assay
on homogenates of five small (<10 mg) pieces each of two different livers (one with a lower
concentration SA (sample A) and one with a higher concentration SA (sample B)), we found that the
coefficient of variation was 31% (19 ± 6 mol/kg tissue) and 49% (68 ± 33 mol/kg tissue), respectively.
To determine if this high variation was due to heterogeneity in SA distribution in the liver or due to
poor precision of the assay for tissue samples, we performed the same work-up on five replicate
aliquots of a homogenate from a large (~50 mg) piece of each of the same livers. In this case, we found
the coefficient of variation to be 9% (20 ± 2 mol/kg) and 7% (85 ± 6 mol/kg), respectively. Thus,
heterogeneity of SA distribution in liver samples accounts for the wide variation in small pieces. We
therefore used only relatively large section of tissue for subsequent analysis.
Pharmacokinetic parameters of SA in mice.
To determine the pharmacokinetics of SA in mice, we injected 200 mg/kg SA intraperitoneally in
C57BL6 mice and measured plasma and tissue concentration at 15, 30, 60, 120, and 240 minutes postinjection (Figure 5A). SA was rapidly absorbed into the systemic circulation with maximal plasma
concentrations achieved within 15 min. Plasma concentrations of SA declined exponentially yielding a
half-life (t1/2) of 62 min. The apparent volume of distribution (V/Fapp), where the bioavailability after
intraperitoneal administration is assumed to be complete (Fapp), was estimated to be 0.16 L, while the
apparent plasma clearance (CL/Fapp) was 1.6 ml/min. Consistent with the large volume of distribution,
tissue concentration of SA were higher than in plasma, with highest concentrations in the kidney
(Figure 5B).
The concentration of SA in plasma and tissue after IP injection spanned the range of SA that is
protective in cell culture experiments. For instance, 100 M SA inhibits formation of KA adducts by
>60% in platelets [15]. SA concentration of 10-100 M protected against sodium channel dysfunction
induced by oxidants in HEK293 cells transfected with human cardiac sodium channel (NaV1.5) or in
the atrial-tumor derived myocyte cell line HL-1 [17]. 500 M SA is sufficient to protect HepG2 cells
against oxidant induced cell death [15].
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Figure 5. Time-dependence of SA concentration in plasma and tissue. SA was injected
200 mg/kg intraperitioneally and remaining concentration of SA (Mean ± range, 2 mice per
time point) determined at various time-points by LC/MS/MS. A) Concentration-time curve
of SA in plasma. B) Concentration-time curve of SA in tissue.
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Feasibility of salicylamine administration in drinking water
KA protein adducts are increased in a wide range of chronic diseases that may require long-term
scavenger treatment to prevent protein adduct accumulation. Repeated administration of SA by
intraperitoneal injection would be less desirable for long-term studies than oral delivery in food or
drinking water. As the acetate salt of SA is readily soluble in water, we determined the feasibility of
administering SA in drinking water. We fed mice 1, 3, and 10 g SA / L drinking water for 7 days and
then measured SA concentrations in plasma and tissue. Increasing concentrations of SA in the drinking
water dose-dependently increased SA concentration in plasma and tissues (Figure 6). Mice given 1 and
3 g/L SA consumed similar volumes of water per day as animals given unmedicated water. At the
highest dose administered, 10 g/L, mice showed signs of toxicity including decreased volume of water
consumed per day, loss of hair and body weight, and also hunching behavior. We estimated that the
mice drank approximately 4.5 ml of water per 24 hour period for the 1 g/L dose (25 µmoles of SA), so
that the bioavailability of SA administered in drinking water is ~38% of that delivered
intraperitoneally. The lower bioavailability of orally delivered SA suggests significant first pass
clearance of SA. While the concentrations of SA obtained by water supplementation at 1 and 3 g/L
were somewhat lower than what was obtained by IP injection, they were still within the range expected
to be therapeutic.
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Figure 6. Tissue concentration of SA as a function of SA drinking water concentration.
Mice were given SA at 1, 3, and 10 g/L in drinking water for 7 days and the level of SA
(Mean ± SEM) in plasma, brain, and liver measured by LC/MS/MS.
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4. Conclusions

The LC/MS/MS assay developed for this study is a sensitive, specific, and accurate method to
measure SA in biological samples. This assay could be used to routinely monitored SA levels even in
the small amount of plasma available from live rodents during long-term treatment studies. Using this
assay, we demonstrated that the plasma and tissue levels of SA obtained after intraperitoneal injection
or supplementation of drinking water are in the appropriate range established by cultured cell
experiments [15,17]. We also demonstrated rapid distribution of SA to plasma and all organs including
brain, confirming that SA can cross the blood brain barrier. Therefore either route of SA
administration could be used, based on the needs of the individual study, to elucidate the role of KAs
in conditions associated with inflammation and oxidative stress. Administration of SA in drinking
water may be less onerous than repeated intraperitoneal injections for examining the role of KA in
animal models of chronic diseases like Alzheimer’s Disease, where continuous elevation in lipid
peroxidation and KA formation over long time periods is likely, so that administration of SA over
similarly long time periods may be required for efficacy.
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